GlycoVaxyn Raises Series A

GlycoVaxyn, a Switzerland-based developer of conjugated vaccines that target bacterial infections, has raised CHF 11.5 million ($9.3m) in Series A funding from seed backers Sofinnova Partners and Index Ventures. www.glaxovaxyn.com